- Home
- REFI vs STRO Comparison
REFI vs STRO Comparison
Compare REFI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- STRO
- Stock Information
- Founded
- REFI 2021
- STRO 2003
- Country
- REFI United States
- STRO United States
- Employees
- REFI N/A
- STRO N/A
- Industry
- REFI Real Estate Investment Trusts
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REFI Real Estate
- STRO Health Care
- Exchange
- REFI Nasdaq
- STRO Nasdaq
- Market Cap
- REFI 306.1M
- STRO 292.6M
- IPO Year
- REFI 2021
- STRO 2018
- Fundamental
- Price
- REFI $16.01
- STRO $2.84
- Analyst Decision
- REFI Buy
- STRO Strong Buy
- Analyst Count
- REFI 2
- STRO 7
- Target Price
- REFI $20.00
- STRO $12.14
- AVG Volume (30 Days)
- REFI 81.4K
- STRO 1.0M
- Earning Date
- REFI 11-07-2024
- STRO 11-13-2024
- Dividend Yield
- REFI 11.74%
- STRO N/A
- EPS Growth
- REFI N/A
- STRO N/A
- EPS
- REFI 2.00
- STRO N/A
- Revenue
- REFI $56,860,278.00
- STRO $160,955,000.00
- Revenue This Year
- REFI N/A
- STRO N/A
- Revenue Next Year
- REFI $4.27
- STRO N/A
- P/E Ratio
- REFI $8.01
- STRO N/A
- Revenue Growth
- REFI 6.49
- STRO 230.90
- 52 Week Low
- REFI $14.82
- STRO $2.45
- 52 Week High
- REFI $17.65
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- REFI 55.62
- STRO 41.69
- Support Level
- REFI $15.94
- STRO $2.66
- Resistance Level
- REFI $16.23
- STRO $2.86
- Average True Range (ATR)
- REFI 0.16
- STRO 0.19
- MACD
- REFI 0.00
- STRO 0.02
- Stochastic Oscillator
- REFI 54.00
- STRO 78.00
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.